Mentor Name: Jenny Poynter

Platinum-based chemotherapy agents have the potential to induce late chemotherapy-induced peripheral neuropathy (CIPN) in patients. Such agents are part of the first-line cancer treatment, and they induce CIPN by causing damage to the dorsal root ganglia and peripheral nerve axons, which leads to sensory and motor deficits. This damage often causes symptoms such as numbness, reduced proprioception, and decreases in motor control, which ultimately interferes with daily activities and social integration. CIPN stands out as a frequent and challenging burden for patients who received platinum-based chemotherapy, particularly in adult men who are treated for testicular germ cell tumor (GCT). Data on the prevalence and predictors of CIPN in pediatric cancer survivors are more limited. It is especially important to evaluate CIPN in survivors of pediatric GCT who receive the same chemotherapy regimen as their adult counterparts. The GCT Outcomes and Late effects Data (GOLD) study is a new cohort of GCT survivors designed to understand how GCT treatment impacts the future health and wellbeing of individuals diagnosed during childhood and adolescence. The primary goal of this project is to collect information surrounding late effects of treatment in the GOLD study, with a particular focus on the consequences of CIPN.